Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.
Last trade$294.10
Day change-$6.065 (-2.02%)
Day range$293.62 – $299.86
Volume758,281
Market cap$79.09B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$79.09B
Price / earnings
13.2×
Price / book
1.82×
Price / sales
0.28×
EV / sales
0.36×
EV / EBITDA
8.99×
Profitability
Earnings per share
$22.73
Return on assets
3.8%
Return on equity
13.81%
Dividend yield
2.06%
Liquidity and leverage
Debt / equity
0.72×
Current ratio
0.84×
Quick ratio
0.74×
Cash ratio
0.11×
Cash flow
Price / cash flow
8.39×
Price / free cash flow
9.57×
Free cash flow
$8.27B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$73.4B
$71.4B
$68.29B
$72.13B
$69.52B
$66.94B
$65.26B
$65.37B
Cost of revenue
$67.09B
$65.13B
$62.02B
$66.06B
$63.37B
$61.02B
$58.9B
$59.19B
Gross profit
$6.31B
$6.26B
$6.27B
$6.08B
$6.14B
$5.93B
$6.37B
$6.19B
Selling, general and administrative
$3.61B
$3.47B
$3.72B
$3.61B
$3.36B
$3.43B
$4.21B
$3.87B
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$4.2B
$3.86B
$4.11B
$4.07B
$3.8B
$3.86B
$4.64B
$4.29B
Operating income
$2.11B
$2.4B
$2.16B
$2.01B
$2.35B
$2.07B
$1.73B
$1.9B
Interest expense
-$333M
-$356M
-$357M
$1.05B
-$347M
-$337M
-$362M
$1.07B
Income before taxes
$2.1B
$2.26B
$2.27B
$1.82B
$2.3B
$2.02B
$1.65B
$2.01B
Income taxes
$401M
$382M
$409M
$543M
$322M
$389M
$239M
$473M
Net income
$1.7B
$1.88B
$1.86B
$1.27B
$1.97B
$1.63B
$1.41B
$1.54B
Net income attributable to common shareholders
$1.44B
$1.66B
$1.65B
$1.23B
$1.87B
$1.53B
$1.32B
$1.42B
EBITDA
$2.98B
$3.06B
$2.81B
$2.73B
$3.04B
$2.75B
$2.41B
$2.54B
Basic earnings per share
$5.49
$6.31
$6.30
$4.67
$7.02
$5.76
$4.88
$5.18
Diluted earnings per share
$5.47
$6.29
$6.26
$4.65
$6.98
$5.71
$4.85
$5.07
Recent news
Company coverage with links to the original publishers.
UnitedHealth Group's Optum Rx segment increased operating earnings by 10.9% to $1.72 billion in Q3 2026 despite a 5.1% decline in adjusted prescriptions, driven by biosimilar adoption and operational efficiencies. However, membership losses and declining prescription volumes pose sustainability challenges for future growth. Specialty pharmacy volumes grew 2.6%, offering some offset to overall volume pressures.
CVS Health announced plans to separate into two independent publicly traded companies by mid-2028: one retaining Aetna, Caremark, and care operations, and another housing retail pharmacies and MinuteClinic. The split aims to improve capital allocation and operating flexibility, though it carries execution risks, restructuring costs, and potential dis-synergies during the transition period.
CVS Health is entering a more constructive earnings phase as Aetna's medical benefit ratio improves, pharmacy operating income rises 10.6%, and operating cash flow reaches $15.32 billion. However, persistent pressure from pharmacy benefit management, medical membership declines, and reimbursement headwinds keep execution risk elevated through 2027.
Cigna Corporation (CI) receives a #3 (Hold) rating on the Zacks Rank with a VGM Score of A. The stock has shown strong momentum with a 4.3% gain over the past four weeks. Nine analysts revised earnings estimates higher in the last 60 days, with the consensus estimate increasing to $30.68 per share and an average earnings surprise of +3.6%.
Cigna Group reported Q3 2026 adjusted EPS of $7.98, beating estimates by 7%, with revenues growing 6.1% to $73.8B. Cigna Healthcare segment showed strong performance with 8.9% revenue growth and 14.9% operating income growth. The company raised its 2026 adjusted EPS outlook to at least $30.60 and Cigna Healthcare's operating income target to $4.6B. However, Evernorth Health Services missed revenue estimates and Pharmacy Benefit Services contributed less than expected.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$1.56 per share
Declared
Oct 28, 2026
Ex-dividend
Dec 3, 2026
Pay date
Dec 17, 2026
Ex-dividend
Amount / share
Pay date
Type
Sep 8, 2026
$1.56
Sep 23, 2026
recurring
Jun 4, 2026
$1.56
Jun 18, 2026
recurring
Mar 5, 2026
$1.56
Mar 19, 2026
recurring
Dec 4, 2025
$1.51
Dec 18, 2025
recurring
Sep 4, 2025
$1.51
Sep 18, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.